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Abstract
Background: Addiction treatment is an effective strategy used to reduce drug-related harm. In the wake of recent
developments in novel addiction treatment modalities, we conducted a longitudinal data analysis to examine
factors associated with inability to access addiction treatment among a prospective cohort of persons who inject
drugs (PWID).
Methods: Data were derived from two prospective cohorts of PWID in Vancouver, Canada, between December
2005 and November 2013. Using multivariate generalized estimating equations, we examined factors associated
with reporting an inability to access addiction treatment.
Results: In total, 1142 PWID who had not accessed any addiction treatment during the six months prior to interview
were eligible for this study, including 364 women (31.9 %). Overall, 188 (16.5 %) reported having sought but were
ultimately unsuccessful in accessing addiction treatment at least once during the study period. In multivariate analysis,
factors independently and positively associated with reporting inability to access addiction treatment included: binge
drug use (Adjusted Odds Ratio [AOR] = 1.65), being a victim of violence (AOR = 1.77), homelessness (AOR = 1.99), and
having ever accessed addiction treatment (AOR = 2.33); while length of time injecting was negatively and
independently associated (AOR = 0.98) (all p < 0.05).
Conclusions: These findings suggest that sub-populations of PWID were more likely to report experiencing difficulty
accessing addiction treatment, including those who may be entrenched in severe drug addiction and vulnerable to
violence. It is imperative that additional resources go into ensuring treatment options are readily available when
requested for these target populations.
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Background
Injecting illegal drugs remains a major public health
concern with current estimates of 16 million users
worldwide [1]. People who inject drugs (PWID) have a
higher probability of contracting infectious diseases in-
cluding HIV, bear an increased burden of morbidity and
mortality, and may suffer from social isolation and
stigma [1–3]. However, the risk of many of the negative
consequences of injection drug use can be reduced by
evidence-based addiction treatment [2], leading to a de-
crease in drug use, HIV risk and criminal behavior as
well as increased likelihood of optimal HIV/AIDS treat-
ment outcomes [4–6].
Now more than ever, a range of novel evidence-based
addiction treatment modalities have been developed, in-
cluding the expanded availability of methadone and use
of both buprenorphine and buprenorphine/naloxone for
opiate addiction as well as residential treatment and out-
patient treatment [7, 8]. In Vancouver, Canada, which is
home to Canada’s largest street-based drug scene [9],
publically funded addiction treatment programs include
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opiate agonist therapy, residential and outpatient treat-
ment and inpatient and outpatient withdrawal manage-
ment, and have recently been increasingly made
available [10, 11].
In many settings, despite various addiction prevention
and care initiatives in place, certain populations of
people who use drugs have previously been shown to ex-
perience increased barriers to access addiction treat-
ment, including Indigenous peoples and persons with
disabilities [12, 13]. Other barriers to treatment experi-
enced by potential patients range from responsibility for
child care, having negative attitudes towards drug treat-
ment staff, and experiencing financial constraints, to the
fear and potential stigmatization of being labelled a drug
user [14–16]. Of concern, those who were unable to ac-
cess addiction treatment have been shown to have
higher rates of HIV risk behaviors and subsequent sero-
conversion to HIV [17, 18]. For this reason, those PWID
who are unable to access addiction treatment may be
among the most vulnerable populations.
Given the well documented benefits of addiction treat-
ment and the serious consequences arising when barriers
to treatment exist, identifying drug-using populations that
experience an inability to access treatment is important.
Doing so will identify patients who may benefit from tar-
geted interventions to increase access to addiction treat-
ment and thus improve their overall health. In the wake of
recent developments in novel addiction treatment modal-
ities, we sought to identify factors independently associ-
ated with an inability to access addiction treatment
amongst PWID in a Canadian setting.
Methods
Study procedures
The Vancouver Injection Drug Users Study (VIDUS) and
the AIDS Care Cohort to evaluate Exposure to Survival
Services (ACCESS) are ongoing open prospective cohorts
of adult drug users recruited through self-referral and
street outreach in Vancouver, Canada. These studies have
been described in detail previously [19]. Briefly, VIDUS
enrolls HIV-negative persons who reported injecting an
illicit drug at least once in the month preceding enroll-
ment; ACCESS enrolls HIV-infected individuals who re-
port using an illicit drug other than marijuana in the
previous month. For both cohorts, other eligibility criteria
included being aged 18 years or older, residing in the
greater Vancouver region and providing written informed
consent. The questionnaire provided is in English only,
however migrants or foreigners are able to participate,
provided they spoke English and reside in the Greater
Vancouver region. Any VIDUS participants who serocon-
verted to HIV during follow-up were transferred to the
ACCESS cohort so that VIDUS includes HIV-negative in-
dividuals only, and ACCESS includes HIV-positive
individuals only. The study instruments and all other
follow-up procedures for each study are essentially identi-
cal to allow for combined analyses. At baseline and semi-
annually thereafter, participants complete the same
interviewer-administered questionnaire eliciting sociode-
mographic data as well as information pertaining to drug
use patterns, risk behaviors, and health care utilization.
Nurses collect blood samples for HIV and Hepatitis C
virus serology, provide basic medical care and arrange re-
ferrals to appropriate health care services if required. Par-
ticipants receive a $30 (CDN) honorarium for each study
visit. The University of British Columbia/Providence
Healthcare Research Ethics Board provided ethical ap-
proval for both studies.
Study sample and primary outcome measure
All participants who were enrolled in the cohorts between
December 1, 2005 and November 30, 2013, and who re-
ported injecting drugs in the six months preceding base-
line were included in the present analysis. Additionally, at
each follow up, the sample was restricted to individuals
who did not report being enrolled in any addiction treat-
ment in the previous six months. The primary outcome of
interest was inability to access addiction treatment in the
previous six months. This was defined as responding “yes”
to the question: “In the past 6 months, have you tried to
access any treatment program but were unable?” The
same question has been used in a previous study, showing
its criterion validity and reliability [17]. In the same ques-
tionnaire, participants were also asked about types of ad-
diction treatment that they were unable to access, which
included inpatient and outpatient detoxification services;
residential treatment and recovery houses; outpatient treat-
ment through community clinics offering opioid agonist
treatment with methadone or buprenorophine/naloxone
and addiction counseling; and twelve-step programmes
(i.e., Narcotics/Cocaine/Alcoholics Anonymous). Partici-
pants were also asked to identify the reasons for why they
were unable to access addiction treatment in an open-
ended question.
Study variables
Based on the literature, we selected explanatory variables
that we hypothesized might be associated with having dif-
ficulty accessing addiction treatment [17, 20, 21]. These
included sociodemographic data, including: age (per year
older); gender (female vs. male); Caucasian (yes vs. no);
homelessness in the previous six months (yes vs. no); em-
ployment in the previous six months (any employment vs.
none); involvement in drug dealing in the previous six
months (yes vs. no); involvement in sex work in the previ-
ous six months (yes vs. no); education attainment (high
school completion or higher vs. less than high school).
Drug-use variables referred to behaviours in the previous
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six months, and included: ≥ daily injection cocaine use
(yes vs. no); ≥ daily injection heroin use (yes vs. no); ≥
daily injection crystal methamphetamine use (yes vs. no);
≥ daily injection prescription opioid use (yes vs. no); ≥
daily crack smoking (yes vs. no); ≥ daily alcohol use (yes
vs. no); and binge drug use, defined as compulsive high-
intensity injection drug use that exceeds normal patterns
of consumption (yes vs. no) [22]. Other variables included:
length of time since initiation of injection drug use (per
year longer); having ever enrolled in drug or alcohol treat-
ment (yes vs. no); experiencing an overdose in the previ-
ous six months (yes vs. no); being a victim of violence,
defined as having been attacked, assaulted, or suffered vio-
lence in the previous six months (yes vs. no); being HCV
antibody positive (yes vs. no); HIV status (being HIV in-
fected and not receiving ART in the previous six months
vs. being HIV infected and receiving ART in the previous
six months vs. HIV negative); and incarceration in the pre-
vious six months (yes vs. no). Since the only difference in
the eligibility criteria between the cohorts was the HIV
serostatus, the HIV serostatus variable was included to ad-
just for the cohort designation.
Statistical analysis
As a first step, we examined the baseline sample charac-
teristics stratified by reports of inability to access addic-
tion treatment, using the Pearson’s Chi-squared test (for
binary variables) and Mann-Whitney test (for continu-
ous variables). Fisher’s exact test was used when one or
more of the cells contained expected values less than or
equal to five.
Since analyses of factors potentially associated with in-
ability to access addiction treatment included serial mea-
sures for each participant, we used generalized
estimating equation (GEE) with logit link, which pro-
vided standard errors adjusted by multiple observations
per person using an exchangeable correlation structure.
Therefore, data from every participant follow-up visit
were considered in this analysis. As a first step, we used
bivariate GEE analyses to determine factors associated
with inability to access addiction treatment. Next, be-
cause our study aimed to identify the set of variables
that best explain a higher odds of inability to access ad-
diction treatment, we used an a priori-defined backward
model selection procedure based on examination of qua-
silikelihood under the independence model criterion
statistic (QIC) to fit a multivariate model. In brief, we
first included all explanatory variables that were associ-
ated with inability to access addiction treatment at the
level of p < 0.10 in bivariate analyses in a full model.
After examining the QIC of the model, we removed the
variable with the largest p-value and built a reduced
model. We continued this iterative process and selected
the multivariate model with the lowest QIC value [23].
In a sub-analysis, we used descriptive statistics to exam-
ine specific addiction treatment modalities that partici-
pants commonly reported being unable to access, and
reasons why they were unable to access the treatment. All
p-values are two sided. All statistical analyses were per-
formed using SAS software version 9.3 (SAS, Cary, NC).
Results
In total, 1142 participants were eligible for the present
study. Among this sample, 364 (31.9 %) were women,
644 (56.4 %) self-reported Caucasian ancestry and the
median age at baseline was 41.9 years (interquartile
range [IQR] = 34.9–48.0). Overall, the 1142 individuals
contributed 5946 observations to the analysis and the
median number of follow-up visits was 3 (IQR: 1–8). Of
the 1142 individuals, 188 (16.5 %) reported a total of 250
reports of inability to access addiction treatment giving
an incidence density of 5.1 reports (95 % confidence
interval [CI]: 4.3–6.1) per 100 person-years. The baseline
characteristics of all participants stratified by reported
inability to access treatment are presented in Table 1.
Also at baseline, compared to ACCESS, VIDUS partic-
ipants were more likely to be young, be Caucasian, inject
heroin or prescription opioids at least daily, have a his-
tory of drug or alcohol treatment, have employment, en-
gage in drug dealing, experience violence, while they
were less likely to engage in binge drug use and be
HCV-positive (all p < 0.05). There were 1988 observa-
tions from ACCESS and 3958 observations from the
VIDUS cohort. Among ACCESS observations, 72 (3.6 %)
involved a report of inability to access addiction treat-
ment, while there were 178 (4.5 %) reports in VIDUS.
There was no significant difference in these reports be-
tween the two cohorts (Chi-square test p-value = 0.113).
The results of the bivariate and multivariate GEE ana-
lyses of factors associated with reporting being unable to
access addiction treatment are presented in Table 2. As
shown, in the final multivariate model, factors that
remained independently associated with inability to ac-
cess addiction treatment included: homelessness (ad-
justed odds ratio [AOR] = 1.99, 95 % CI: 1.47–2.69), time
since initiating injecting drug use (AOR = 0.98, 95 % CI:
0.97–1.00), having ever accessed drug or alcohol treat-
ment (AOR = 2.33, 95 % CI: 1.47–3.68), binge drug use
(AOR = 1.65, 95 % CI: 1.26–2.16), and being a victim of
violence (AOR = 1.77, 95 % CI: 1.29–2.42).
In the sub-analysis, the top three treatment modalities
that participants were seeking but unable to access in-
cluded inpatient detoxification services (66.4 %), in-
patient treatment centres (14.8 %), and recovery houses
(13.2 %), as shown in Table 3. Table 4 presents self-
reported reasons for being unable to access addiction
treatment. Being placed on a waitlist (58.4 %) was the
primary reason participants gave for being unable to
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access addiction treatment, followed by the program not
accepting couples (8.0 %) and being turned down by the
treatment program (7.6 %).
Discussion
We found that a substantial proportion of our study sam-
ple of PWID in Vancouver, Canada who were not enrolled
in addiction treatment were unable to access addiction
treatment despite motivated to do so. In the multivariate
analysis, unsuccessful attempts to engage in addiction
treatment were independently and positively associated
with periods of homelessness, having ever been in drug or
alcohol treatment, binge drug use, and reporting being a
victim of violence, and were independently and negatively
associated with length of time since initiating injecting
drug use. The most common addiction treatment modal-
ities reported to be inaccessible included inpatient
detoxification, inpatient treatment centres, and place-
ment at a recovery house. Though a variety of reasons
were cited for inability to access addiction treatment,
being placed on a waitlist, programs not accepting cou-
ples, and being turned down by program were the most
common.
Our finding that PWID with longer injecting careers were
less likely to experience inability to access addiction treat-
ment has not been reported in previous studies, although a
previous Australian study did find that long term drug
users were more commonly in treatment [24]. These find-
ings collectively demonstrate the need to ensure those indi-
viduals with shorter drug injecting histories have increased
access to treatment in order to minimize future conse-
quences of long term drug use, including declining health
and increasing risk of death [25]. Additional studies under-
standing the differences in needs between individuals with
Table 1 Baseline sample characteristics, stratified by reporting inability to access addiction treatment in the past six months among
PWID in Vancouver, Canada (n = 1142)




n (%) 68 (6.0)
No
n (%) 1074 (94.0)
Age (median, IQR) 39 (32–44) 42 (35–48) 0.008
Female gender 24 (35.3) 340 (31.7) 1.18 (0.70–1.97) 0.533
Caucasian 40 (58.8) 604 (56.2) 1.11 (0.68–1.83) 0.677
Homelessnessa 45 (66.2) 392 (36.5) 3.73 (2.19–6.35) <0.001
Daily injection cocaine usea 11 (16.2) 101 (9.4) 1.85 (0.94–3.64) 0.071
Daily injection heroin usea 32 (47.1) 361 (33.6) 1.75 (1.07–2.86) 0.025
Daily injection meth usea 1 (1.5) 56 (5.2) 0.27 (0.04–1.98) 0.200
Daily injection prescription opioid usea 27 (39.7) 310 (28.9) 1.62 (0.98–2.67) 0.059
Daily crack smokinga 29 (42.7) 422 (39.3) 1.15 (0.70–1.89) 0.583
Daily alcohol usea 6 (8.8) 87 (8.1) 1.11 (0.47–2.65) 0.806
Years since first injection drug use (median, IQR) 17 (11–22) 19 (11–28) 0.084
Drug or alcohol treatment Ever 59 (86.8) 804 (74.9) 2.20 (1.08–4.50) 0.027
Employmenta 21 (30.9) 258 (24.0) 1.41 (0.83–2.41) 0.202
Drug dealinga 36 (52.9) 335 (31.2) 2.48 (1.51–4.06) <0.001
Sex worka 7 (10.3) 150 (14.0) 0.72 (0.32–1.60) 0.413
High school degree 40 (58.8) 500 (46.6) 1.64 (0.99–2.72) 0.051
Overdosea 6 (8.8) 66 (6.2) 1.48 (0.62–3.54) 0.372
Binge drug usea,b 35 (51.5) 400 (37.2) 1.77 (1.08–2.90) 0.021
A victim of violencea 26 (38.2) 230 (21.4) 2.25 (1.35–3.74) 0.002
HCV positive 58 (85.3) 941 (87.6) 0.78 (0.39–1.57) 0.490
HIV+ and not on ARTa 10 (14.7) 164 (15.3) 0.88 (0.44–1.77) 0.720
HIV+ and on ARTa 9 (13.2) 203 (18.9) 0.64 (0.31–1.32) 0.225
Incarcerationa 20 (29.4) 187 (17.4) 1.97 (1.14–3.39) 0.013
Note: The p-value for variable age was obtained from Mann-Whitney test; exact mid p-values for daily injection meth use and overdose were obtained from
Fisher’s exact test; and for other binary variables p-values were obtained from Chi-square test with degree of freedom = 1
PWID people who inject drugs, CI confidence interval, IQR interquartile range
aDenotes activities in the previous six months
bRefers to any route of consumption (i.e., sniffing, snorting, smoking or injecting)
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Table 2 Bivariate and multivariate GEE analyses of factors associated with inability to access addiction treatment among PWID in
Vancouver, Canada (n = 1142)
Characteristic Unadjusted Adjusted
Odds ratio (95 % CI) p - value Odds ratio (95 % CI) p - value
Age
(per year older) 0.97 (0.96–0.98) <0.001
Gender
(female vs. male) 1.42 (1.03–1.95) 0.033 1.37 (0.98–1.92) 0.062
Ethnicity
(Caucasian vs. other) 0.82 (0.60–1.12) 0.205
Homelessnessa
(yes vs. no) 2.53 (1.92–3.33) <0.001 1.99 (1.47–2.69) <0.001
Daily injection cocaine usea
(yes vs. no) 1.58 (1.04–2.41) 0.032
Daily injection heroin usea
(yes vs. no) 1.69 (1.24–2.31) <0.001
Daily injection meth usea
(yes vs. no) 1.15 (0.61–2.15) 0.669
Daily injection prescription opioid usea
(yes vs. no) 1.51 (1.11–2.07) 0.010
Daily crack smokinga
(yes vs. no) 1.30 (0.98–1.74) 0.073
Daily alcohol usea
(yes vs. no) 1.37 (0.90–2.11) 0.144
Length of time injecting drugs
(per year longer) 0.98 (0.97–0.99) <0.001 0.98 (0.97–1.00) 0.045
Drug or alcohol treatment ever
(yes vs. no) 2.36 (1.51–3.68) <0.001 2.33 (1.47–3.68) <0.001
Any employment (reg, temp, self) a
(yes vs. no) 1.02 (0.74–1.42) 0.888
Drug dealinga
(yes vs. no) 1.90 (1.42–2.55) <0.001 1.32 (0.96–1.83) 0.090
Sex worka
(yes vs. no) 1.04 (0.67–1.61) 0.861
High school degree or higher
(yes vs. no) 1.15 (0.84–1.58) 0.379
Overdosea
(yes vs. no) 1.45 (0.85–2.49) 0.175
Binge drug usea,b
(yes vs. no) 1.76 (1.37–2.25) <0.001 1.65 (1.26–2.16) <0.001
A victim of violencea
(yes vs. no) 2.19 (1.62–2.97) <0.001 1.77 (1.29–2.42) <0.001
HCV positive
(yes vs. no) 0.97 (0.59–1.61) 0.916
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variations in their length of injecting history may aid in ad-
dressing the barriers specific to newer users.
We identified a positive and independent association
between an inability to access addiction treatment and
binge drug use. This is particularly alarming as binge
drug use has been identified as an independent risk fac-
tor of HIV seroconversion [22]. Somewhat surprising
was our finding of an association between having ever
been in drug or alcohol treatment and being unable to
access addiction treatment, as this result has not been
previously demonstrated. A negative association was
previously identified between exposure to addiction
treatment and attaining stable housing, suggesting that a
history of addiction treatment may be a marker of severe
drug addiction [26]. A recent Swiss study utilized an ad-
vanced statistical method to assess opioid agonist ther-
apy utilization patterns and found that the time until
readmission shortened as the number of treatment epi-
sodes increased [27]––a finding that somewhat contra-
dicts our result. As cycling in and out of treatment is
common among people with any substance use disor-
ders, future research could apply such method to investi-
gate patterns of participation in other treatment
modalities, including detoxification services, and extend
our finding. Regardless, it is essential that individuals
who wish to enter treatment have the opportunity re-
gardless of previous attempts.
We also identified a positive and independent associ-
ation between being a victim of violence and reporting
an inability to access addiction treatment. As previously
reported, PWID are subjected to elevated levels of vio-
lence compared to the general population, commonly
due to inextricable involvement in unpredictable drug
market situations and informal activities, such as drug
dealing, sex work and theft [28–30]. Individuals en-
gaging in prohibited income generating activities also
show more intense drug use patterns [31]. As a result of
the violence experienced, many individuals will increase
their drug use, experience physical injuries, and display
an increase in mental health symptoms, all of which may
have long term impacts on their health [32, 33]. Further,
women who experience partner based violence often
also have a lack of social support to actively pursue ad-
diction treatment [34]. It is particularly concerning that
those experiencing violence have difficulty accessing
treatment, as this vicious cycle could be stopped by en-
gaging PWID in addiction treatment to avoid partaking
in risky drug use environments.
We also found that inpatient detoxification was the
most common addiction treatment modality that par-
ticipants were unable to access, with waitlists being
the primary reason for this inaccessibility. This is
consistent with previous studies showing that among
referrals to a Vancouver-based in-patient detoxifica-
tion, 35 % of clients dropped off the waitlist prior to
commencing treatment [35]. Being placed on a wait-
list has also been shown to decrease retention when
in receipt of treatment, a problem which has been
demonstrated not only in this setting, but other set-
tings as well [35–37]. However, the criteria for requir-
ing inpatient detoxification are evolving with stand-
alone detoxification (without longer term outpatient
treatment) being no longer advised in most cases of
opioid addiction and in some cases of alcohol addic-
tion [38, 39]. However, our findings do diverge from our
past work that found disparities in access to addiction
treatment based on ethnicity/ancestry [12], and is encour-
aging that we no longer find that people of non-Caucasian
Table 2 Bivariate and multivariate GEE analyses of factors associated with inability to access addiction treatment among PWID in
Vancouver, Canada (n = 1142) (Continued)
HIV and treatment statusa
(HIV+ and not on ART vs HIV−) 0.93 (0.59–1.46) 0.748
(HIV+ and on ART vs HIV_HIV−) 0.76 (0.50–1.14) 0.186
Incarcerationa
(yes vs. no) 1.68 (1.17–2.42) 0.005
GEE generalized estimating equations, PWID people who inject drugs, CI confidence interval
aDenotes activities in the previous six months
bRefers to any route of consumption (i.e., sniffing, snorting, smoking or injecting)
Table 3 Treatment modalities participants were unable to
access among PWID in Vancouver, Canada (n = 250)
Treatment modality Number of reports % of reports
Detox/youth detox 139 55.6
Treatment centre 38 15.2
Recovery House 33 13.2
Methadone or Suboxone 18 7.2
Counsellor 11 4.4
Daytox 6 2.4
Twelve-step programmes 3 1.2
Residential community 2 0.8
Out-patient treatment 2 0.8
Cocaine treatment program 0 0.0
Drug treatment court 0 0.0
PWID people who inject drugs
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ancestry were more likely to experience difficulty obtain-
ing addiction treatment, suggesting that recent efforts to
scale-up access to treatment options, may be demonstrat-
ing positive results [10, 12]. In this particular setting in
Vancouver, Canada, low threshold access to opioid
agonist treatment is widely available through the uni-
versal no-cost medical insurance plan with the co-
operation of community physicians and pharmacies.
As a result of this integration participants would typ-
ically not have as much difficulty accessing opioid
agonist treatment compared to other treatment
modalities.
This study has several limitations. First, the VIDUS
and ACCESS cohorts are not random samples and
therefore may not generalize to other populations of
PWID. Second, data collection was based on self-
report and thus could be subject to reporting bias, in-
cluding socially desirable responses which may have
resulted in under-reporting of illicit drug use and
other stigmatized behaviours. As a result, the preva-
lence of some risk behaviours may have been under-
estimated in the present study. However, self-reported
risk behaviour has been shown to be largely accurate
among adult drug-using populations [40]. Third, there
were no variables representing family and social net-
working, which may have been important factors to
analyze and should be included in future research.
Lastly, as with any observational research, unmeas-
ured confounders may exist that were not accounted
for in our analyses and contributed to the overall
results.
Conclusion
In summary, despite the recent increasing support for
addiction treatment in Vancouver [10], our findings indi-
cate that some sub-populations of PWID are more likely
to be marginalized from accessing addiction treatment
services, including those who are homeless, those with
shorter injecting careers, those who report binge drug
use, those with previous alcohol or drug treatment ex-
perience, and those who report experiencing violence.
Given that the primary reason we identified for inability
to obtain addiction treatment was waitlists, it is impera-
tive that additional resources go into ensuring treatment
options are readily available when requested. Addition-
ally, this study identified the need for targeted interven-
tions for patient populations suffering severe negative
consequences of their addiction as they are often the
ones having a difficult time accessing treatment.
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